# US 2025/0205264 A1 · Methods of using avermectin compositions for the treatment of spasticity and dosing regimens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0205264 A1
- Document ID: US20250205264A1
- Status: Published application
- Kind: A1
- Application number: 18/849,407
- Filed: 2023-03-22
- Published: 2025-06-26
- Earliest claimed: 2022-03-22
- Assignees: L4 Bio LLC
- Applicants: L4 Bio LLC
- Inventors: Samuel D. Waksal; Rui Wu; Alexandra Zanin-Zhorov
- Web page: https://patentgrep.com/patent/US20250205264A1

## CPC

- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 9/4858: {Organic compounds}
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/433: Thidiazoles
- A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine}
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are formulations and dosage forms of avermectins, and particularly of ivermectin. The disclosed compositions may be used in methods for the treatment and prevention of spasticity in humans.

## Claims

### Claim 1

A method of treating or preventing spasticity, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising:
(i) about 1% to about 15% of a compound, wherein the compound is a compound of Formula I:
or a pharmaceutically acceptable salt, stereoisomer, polymorph, solvate, or isotopically labeled compound thereof, wherein
each occurrence of X is independently selected from —CH2—, —NH—, —O—, —S—, —SO— and —SO2—;
Y is selected from —CH2—, —O—, —NH—, and —S—;
Z is selected from O and S;
each occurrence of is a single bond or a double bond;
n is an integer 0-6; and
each occurrence of R1 is independently selected from halogen, —R, —OR, —NO2, —NCS, —CN, —CF3, —OCF3, —NHR, —N(R)2, —OC(O)R, —C(O)OR, —SR, —C(O)R, —C(O)C(O)R, —C(O)CH2C(O)R, —C(S)R, —C(S)OR, —C(O)C(O)OR, —C(O)C(O)N(R)2, —C(O)N(R)2, —OC(O)N(R)2, —C(S)N(R)2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(S)R, —N(R)C(O)N(R)2, —N(R)C(S)N(R)2, —N(COR)COR, —N(OR)R, —C(═NH)N(R)2, —C(O)N(OR)R, —C(═NOR)R, —OP(O)(OR)2, —P(O)(R)2, —P(O)(OR)2, —P(O)(H)(OR), —CH2—OR, and —CH2—O—CH2—R;
each occurrence of R2 is independently selected from independently selected from H, OH, O—C1-4alkyl, —OC(O)C1-4alkyl, —OC(O)NH2, and —OC(O)NHC1-4alkyl;
each occurrence of R3 is mono, di, or triglycoside, or OC(O)—(C3-C5)alkenyl;
each R is independently selected from H, —(C1-C12)alkyl, —(C3-C10)-cycloalkyl, (C3-C10)-cycloalkenyl, —[(C3-C10)cycloalkyl]-(C1-C12)alkyl, —[(C3-C10)cycloalkenyl]-(C1-C12)alkyl, —[(C3-C10)cycloalkenyl]-(C1-C12)alkyl, —[(C3-C10)cycloalkyl]-O—(C1-C12)alkyl, —[(C3-C10)cycloalkenyl]-O—(C1-C12)alkyl, —(C6-C10)aryl, (C6-C10)aryl-(C1-C12)alkyl, —(C6-C10)aryl-O—(C1-C12)alkyl, (C6-C10)aryl-N(R″)—(C1-C12)alkyl, 3- to 10-membered heterocyclyl, (3- to 10-membered heterocyclyl)-(C1-C12)alkyl, (3- to 10-membered heterocyclyl)-O—(C1-C12)alkyl, (3- to 10-membered heterocyclyl)-N(R″)—(C1-C12)alkyl, 5- to 10-membered heteroaryl, (5- to 10-membered heteroaryl)-(C1-C12)-alkyl, (5- to 10-membered heteroaryl)-O—(C1-C12)-alkyl and (5- to 10-membered heteroaryl)-N(R″)—(C1-C12)-alkyl;
each heterocyclyl has 1-4 heteroatoms independently selected from N, NH, O, S, SO, and SO2, and
heteroaryl has 1-4 heteroatoms independently selected from N, NH, O, and S;
each occurrence of R is independently unsubstituted or is substituted with 1 to 5 R′;
each occurrence of R′ is halo, OH, oxo, —CH2OR″, —CH2N(R″)2, C(O)N(R″)2, —C(O)OR″, —NO2, —NCS, —CN, —CF3, —OCF3 and —N(R″)2; and
each occurrence of R″ is independently H, C1-6 alkyl, C2-6 alkenyl, C3-6 cycloalkyl, C3-6 cycloalkenyl, 3- to 6-membered heterocyclyl, 5- to 10-membered heteroaryl, and (C6-C10)-aryl;
(ii) about 20% to about 40% of a first surfactant comprising one or more of:
(a) mono-, di-, and/or tri-fatty acid esters of glycerol;
(b) mono- and/or di-fatty acid esters of 1,2-propylene glycol; and
(c) mono- and/or di-fatty acid esters of polyethylene glycol wherein the fatty acids are selected from C6 to C10 fatty acids; and
(iii) about 15% to about 70% of a second surfactant selected from one or more of a polysorbate surfactant and/or a fatty acid ester of sorbitan.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound is a compound of Formula II:
or a pharmaceutically acceptable salt, stereoisomer, polymorph, solvate or isotopically labeled compound thereof, wherein n, R1, R2, and R3 are each as defined in Formula I.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the compound is a compound of Formula III:
or a pharmaceutically acceptable salt, stereoisomer, polymorph, solvate or isotopically labeled compound thereof, wherein R1, R2, and R3 are each as defined in Formula I.

### Claim 4

The method of any one of the preceding claims, wherein the compound is a compound of Formula IV:
or a pharmaceutically acceptable salt, stereoisomer, polymorph, solvate or isotopically labeled compound thereof, wherein
each occurrence of R1 is independently selected from halogen, —R, —OR, —NO2, —NCS, —CN, —CF3, —OCF3, —NHR, —N(R)2, —OC(O)R, —C(O)OR, —C(O)N(R)2, —OC(O)N(R)2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)N(R)2, —CH2—OR, and —CH2—O—CH2—R;
each occurrence of R3 is mono, di, or triglycoside, or OC(O)—(C3-C5) alkenyl; and
R, R′ and R″ are each as defined in Formula I.

### Claim 5

The method of any one of the preceding claims, wherein the compound is a compound of Formula V:
or a pharmaceutically acceptable salt, stereoisomer, polymorph, solvate or isotopically labeled compound thereof, wherein
each occurrence of R1 is independently selected from halogen, —R, —OR, —NO2, —NCS, —CN, —CF3, —OCF3, —NHR, —N(R)2, —OC(O)R, —C(O)OR, —C(O)N(R)2, —OC(O)N(R)2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)N(R)2, —CH2—OR, and —CH2—O—CH2—R; and
R, R′ and R″ are each as defined in Formula I.

### Claim 6

The method of any one of the preceding claims, wherein the pharmaceutical composition comprises about 1% to about 15% ivermectin comprising a compound of Formula VI and a compound of Formula VII:

### Claim 7 (depends on 6)

The method of claim 6, wherein the ivermectin comprises at least about 70% of a compound of Formula VI and less than about 30% of a compound of Formula VII.

### Claim 8 (depends on 7)

The method of claim 7, wherein the ivermectin comprises at least about 90% of a compound of Formula VI and less than about 10% of a compound of Formula VII.

### Claim 9

The method of any one of the preceding claims, wherein the pharmaceutical composition comprises about 3% to about 12% of ivermectin.

### Claim 10 (depends on 9)

The method of claim 9, wherein the pharmaceutical composition comprises about 5% to about 10% of ivermectin.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1 to 10, wherein the fatty acids for the first surfactant are selected from C8 to C10 fatty acids.

### Claim 12 (depends on 11)

The method of claim 11, wherein the first surfactant comprises mono- and di-fatty acid esters of glycerol.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1 to 12, wherein the first surfactant is selected from Masester M8120, Capryol 90, Labrasol ALF, and combinations thereof.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1 to 13, wherein the second surfactant is selected from polysorbate 80 (Tween 80), sorbitan monolaurate (Span 20), and combinations thereof.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1 to 14 comprising about 25% to about 30% of the first surfactant.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1 to 15 comprising about 15% to about 20% of the second surfactant.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1 to 15 comprising about 30% to about 35% of the second surfactant.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1 to 15 comprising about 60% to about 65% of the second surfactant.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1 to 17, further comprising about 5% to about 55% vitamin E TPGS; or about 30% to about 50% vitamin E TPGS.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1 to 10 comprising: (i) about 5% to about 10% ivermectin; (ii) about 25% to about 30% mono- and di-C8 to C10 fatty acid esters of glycerol; (iii) about 15% to about 30% of a polysorbate surfactant; and (iv) about 30% to about 50% vitamin E TPGS.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1 to 10 comprising: (i) about 8% ivermectin; (ii) about 27.6% mono- and di-C8 to C10 fatty acid esters of glycerol; (iii) about 32.2% polysorbate 80; and (iv) about 32.2% vitamin E TPGS.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1 to 10 comprising: (i) about 8% ivermectin; (ii) about 27.6% Masester E8120; (iii) about 32.2% polysorbate 80; and (iv) about 32.2% vitamin E TPGS.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method according to any one of claims 1 to 10 comprising: (i) about 8% ivermectin; (ii) about 27.6% mono- and di-C8 to C10 fatty acid esters of glycerol; (iii) about 18.4% polysorbate 80; and (iv) about 46% vitamin E TPGS.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1 to 10 comprising: (i) about 8% ivermectin; (ii) about 27.6% Masester E8120; (iii) about 18.4% polysorbate 80; and (iv) about 46% vitamin E TPGS.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 1 to 24, wherein the pharmaceutical composition is administered to the subject in a pharmaceutical dosage form comprising the composition in a gelatin capsule.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method any one of claims 1-25, wherein the spasticity is secondary to multiple sclerosis, a spinal cord injury, a stroke, or a brain injury.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method any one of claims 1-25, wherein the spasticity is spinal spasticity.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 1-27, wherein the spasticity is not secondary to cerebral palsy.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 1-27, wherein the treatment reduces hyper-reflexia in the human subject.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein the spasticity is secondary to a spinal cord injury, and wherein the method further comprises beginning administering to the human subject a dose of the formulation after the spinal cord injury and before the spasticity develops.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein the spasticity is secondary to multiple sclerosis, wherein the method further comprises beginning administering to the human subject a dose of the formulation after a diagnosis of the multiple sclerosis and before the spasticity develops.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein administering the formulation is effective to increase connexin 36 levels in spinal cord neuron.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein administering the formulation is effective to increase gap junctions in neurons in the spinal cord or increase electrical coupling between neurons in the spinal cord.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein the spasticity is associated with inflammation.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 1-34, wherein the subject is a mammal.

### Claim 36 (depends on 35)

The method of claim 35, wherein the mammal is a human.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 1-36, wherein about 10 mg to about 120 mg of the compound is administered to the subject.

### Claim 38 (depends on 37)

The method of claim 37, wherein about 10 mg to about 80 mg of the compound is administered to the subject.

### Claim 39 (depends on 37)

The method of claim 37, wherein about 20 mg to about 40 mg of the compound is administered to the subject.

### Claim 40 (depends on 37)

The method of claim 37, wherein about 10 mg, about 20 mg, about 40 mg, about 60 mg, about 80 mg, or about 120 mg of the compound is administered to the subject.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method of any one of the claims 1-40, wherein the pharmaceutical composition is administered once a day, every other day, or every three days.

### Claim 42 (depends on 41)

The method of claim 41, wherein the pharmaceutical composition is administered once a day.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 1-42, wherein the pharmaceutical composition is administered for at least 14 days.

### Claim 44 (depends on 43)

The method of claim 43, wherein the pharmaceutical composition is administered for about 14 days, for about 30 days, for about 60 days, for about 84 days, for about 90 days, or continuously.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 1-44, wherein the pharmaceutical composition is administered as a single dose on each day the pharmaceutical composition is administered.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 1-44, wherein the pharmaceutical composition is administered in the form of several divided doses on each day the pharmaceutical composition is administered.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 1-46, the method further comprising administering to the human subject another therapeutic agent.

### Claim 48 (depends on 47)

The method of claim 47, wherein the other therapeutic agent is baclofen, benzodiazepines, diazepam, clonazepam, dantrolene, or tizanidine.
